CN102631623A - Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof - Google Patents
Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof Download PDFInfo
- Publication number
- CN102631623A CN102631623A CN2012100548642A CN201210054864A CN102631623A CN 102631623 A CN102631623 A CN 102631623A CN 2012100548642 A CN2012100548642 A CN 2012100548642A CN 201210054864 A CN201210054864 A CN 201210054864A CN 102631623 A CN102631623 A CN 102631623A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- traditional chinese
- thyroid
- associated ophthalmopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and a preparation method of the traditional Chinese medicine composite. The traditional Chinese medicine composite is prepared from the following traditional Chinese medicines in parts by weight: 30-60 parts of radix curcumae, 30-60 parts of root of common peony, 30-80 parts of salviae miltiorrhizae, 60-120 parts of semen coicis, 20-60 parts of thunberg fritillary bulb, 10-30 parts of stiff silkworm and 30-80 parts of semen litchi. The invention designs a multi-time extraction technical route by taking water as a solvent. The traditional Chinese medicine composite disclosed by the invention can effectively lower the exophthalmos degree of the disease eye of the thyroid associated ophthalmopathy, and the total effective rate is 86.9%; the total effective rate of the main eye symptom and the sign integral curative effect of the disease eye of the thyroid associated ophthalmopathy is 91.8%; the total effective rate of the Chinese medicine syndrome integral curative effect of the thyroid associated ophthalmopathy patient is 90.3%; the lesion activity grade of the disease eye of the thyroid associated ophthalmopathy can be effectively improved; and the thyroid function of the patient can be improved. The traditional Chinese medicine composite has high safety. The invention also discloses a preparation method for the traditional Chinese medicine composite granule.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation method thereof, relate in particular to a kind of preparation treatment Thyroid-related Ophthalmopathy (thyriod associated ophthalmopathy, Chinese medicine composition TAO) and preparation method thereof.
Background technology
(thyriod associated ophthalmopathy is a kind of organ specificity autoimmune disease relevant with abnormal thyroid function TAO) to Thyroid-related Ophthalmopathy, is to cause the pop-eyed common cause of adult simple eye and eyes.Claim thyroid dependency immunity orbital disease, infiltrative exophthalmos, Graves oculopathy etc. again.Because The development in society and economy, rhythm of life are accelerated, operating pressure increases, iodine is taken in factors such as increase, the patient of abnormal thyroid function obviously increases, and the sickness rate of relevant TAO also rises year by year with it.The prevalence of TAO has reached 1% according to statistics, and TAO has become the modal orbit diseases of domestic and international adult.
The definite pathogenesis of TAO it be unclear that, but present research data shows: TAO be a kind of maybe with relevant multi-factor diseases such as gene, autoimmune, eye socket fibroblast increased activity, environmental factors.Though TAO is the multifactor a kind of disease that causes; But it has common histopathology to change---extraocular muscles edema, lymphocytic infiltration, myodegeneration necrosis and fibrosis; Fat and connective tissue fibroblast are active behind the socket of the eye endosphere, mucopolysaccharide deposition and edema.The extraocular muscles limitation of activity of edema causes diplopia, extraocular muscles contracture, further can cause exposure keratitis, and extraocular muscles and eye socket tissue edema also can be oppressed optic nerve to cause visual function impaired etc.
The course of disease two stages of experience of TAO: be active stage in early days, mainly show as eye lymphocytic infiltration, GAG deposition and edema; Then show as the deposition of retrobulbar tissue's fibrosis and fat late period.In the treatment of this disease, stress that early stage active and effective treatment is the important measures of its complication of prevention.Can carry out the judge of pathological changes activeness point system according to eye symptom such as pain, hyperemia, edema, expophthalmos degree and the eye function state etc. of TAO clinically.
Because its immunosuppressant therapy that is adopted of pathological changes different times or radiocurable curative effect are different, and the Therapeutic Method that the pathological changes weight is taked is different.Therefore, often adopt treatment by stages clinically, stress active stage TAO is treated.Its treatment measure mainly comprises: (1) eye protection property treatment.(2) medicine anti-inflammatory treatment, promptly during the eye socket acute inflammation, whole body is used glucocorticoid or immunosuppressant, to alleviate the infringement of extraocular muscles, alleviates edema and to the compressing of optic nerve.But whole body is widely applied, and the side effect of glucocorticoid is big, relapse rate is high after the drug withdrawal, also has the doctor to adopt Ciclosporin A treatment Thyroid-related Ophthalmopathy to obtain curative effect preferably, but the side effect of Ciclosporin A is also big and cost an arm and a leg.(3) operation and radiotherapy.Along with a large amount of patients TAO are difficult to tolerate disease relapse after the side effect of using glucocorticoid or immunosuppressant and the drug withdrawal or use situation such as the curative effect of glucocorticoid or immunosuppressant is unsatisfied with increasing, the TAO patient who seeks therapy of combining Chinese and Western medicine obviously increases.Therefore, developmental research can improve the TAO therapeutic effect and toxicity is little, the Chinese medicine of side effect that can obviously reduce glucocorticoid and immunosuppressant is imperative.
Though motherland's medical science does not have the record of primary disease name of disease, in ancient books, record its similar clinical manifestation, say like Effective Formulas Tested by Physicians for Generations: " take turns hard and unable to move around, this is that Gu (h ǔ) eye coagulates eyeball "; " order is through great achievement " meaning: " this disease stiffness of the nape, flushed complexion is dry, order such as fire expand between eyelid, can not open and close, if wild mausoleum demon with the order of flower cylinder change fish, dashes forward and fixed coagulating, so say eye unclosed due to exophthalmos ".Symptom that these documents are described and sign are similar to modern medicine active stage TAO.The new century whole nation high Chinese medicine universities and colleges' planning teaching materials " ophthalmology of Chinese medicine " are thought that primary disease is similar to and are cured nationality contained " orbital pseudotumor or tumor " ancient times.
Mostly the clinical research of Chinese medicine thyroid-associated ophthalmopathy is the case report, and most reports are not established matched group.Comprehensive existing research report can be summarized as: (1) determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs; (2) folk prescription treatment; (3) according to the treatment by stages of pathological changes situation.(Wang Dezhen. the cognition of Chinese medicine thyroid eye diseas, " modern combination of Chinese and Western medicine journal, 2009,18 (11): 1261; Once flat, etc. the clinical observation of the early stage thyroid-associated ophthalmopathy of Chinese traditional treatment, " Chinese TCM Ophthalmology journal, 2008,18 (2): 67; Yuan Xiaohui, etc. therapy of combining Chinese and Western medicine Thyroid-related Ophthalmopathy, " Chinese TCM Ophthalmology journal, 2006,16 (1): 16; Zhou Huaxiang, etc. TCM Ophthalmology to the understanding and the treatment of orbital pseudotumor or tumor, " the Sichuan traditional Chinese medical science ", 2006,24 (12): 19)
Applicant of the present invention realizes in research of treating TAO for many years and clinical practice: thyroid-associated ophthalmopathy is mainly in young and middle-aged people; Since the patient of this age bracket be in enter a higher school, periods such as promotion of employment and career; Often stay up late all day, overworked eyes, excessive thinking, so the morbidity of primary disease is relevant with the liver spleen.Because of liver controlling conveyance and dispersion, main muscle, harmonizing the functional activities of vital QI.The irritability bar reaches, and then QI and blood relaxes soft with smooth, muscle.If depressed emotion, depression of liver-QI loses bar and reaches, and catharsis mistake department is then qi-blood disharmony, move not smooth, qi depression to blood stasis; Transverse invasion of hyperactive liver-QI is violated spleen, or the excessive thinking impairment of the spleen, dysfunction of the spleen in transportation, and water liquid fortuneization mistake department, endogenous damp formation gathers and forms drink and give birth to expectorant, phlegm and blood stasis, venation plug knot, muscle convulsion are unfavorable, are second-class disease so occur that the order pearl is given prominence to, rotation is ineffective, look one.Therefore, mostly the primary disease pathogenesis is qi depression to blood stasis, retention of water-damp in the body, phlegm and blood stasis, and the muscle convulsion is unfavorable.
Summary of the invention
The purpose of this invention is to provide Chinese medicine composition of a kind of treatment Thyroid-related Ophthalmopathy (TAO) and preparation method thereof.Use this traditional Chinese medicine composition for treating TAO can not only obviously alleviate the most outstanding symptom of this disease---eyeball protrusion and eye cardinal symptom and sign, and can also obviously reduce the TAO activeness and mark, improve patient's tcm syndrome, alleviate patient's general malaise symptom.
The objective of the invention is to realize through following technical scheme:
Chinese medicine composition of the present invention is made up of the following traditional Chinese medicines compositions: Radix Curcumae, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Bulbus Fritillariae Thunbergii, Semen Coicis, Bombyx Batryticatus, Semen Litchi, water surplus.
Each composition parts by weight of further Chinese medicine composition of the present invention are: Radix Curcumae 30-60 part, Radix Paeoniae Rubra 30-60 part, Radix Salviae Miltiorrhizae 30-80 part, Semen Coicis 60-120 part, Bulbus Fritillariae Thunbergii 20-60 part, Bombyx Batryticatus 10-30 part, Semen Litchi 30-80 part, water surplus.
Each composition parts by weight of Chinese medicine composition most preferably of the present invention are: 60 parts of Radix Curcumaes, 45 parts of Radix Paeoniae Rubra, 30 parts of Radix Salviae Miltiorrhizaes, 120 parts of Semen Coiciss, 20 parts of Bulbus Fritillariae Thunbergiis, 15 parts of Bombyx Batryticatus, 80 parts of Semen Litchis, water surplus.
The main effective ingredient of the present invention dissolves in boiling water, takes all factors into consideration the character and the preparation technology of we when clinical use of combination of Chinese medicine thing effective ingredient, is the extraction process route of solvent with water so designed.Preparation technology's flow process is following:
(1) gets said each the composition weight umber mix homogeneously of above-mentioned Chinese medicine composition;
(2) step (1) mixture is added 8 times of water yields of mixture total weight amount umber and decocted 1～1.5 hour, filter, it is for use to filtrate;
(3) step (2) filtering residue is added 6 times of water yields of step (1) mixture total weight amount umber again and decocted 1～1.5 hour, filter, it is for use to filtrate;
(4) with above-mentioned twice filtrating merge Chinese medicine composition solution;
(5) merge step (4) to such an extent that Chinese medicine composition solution concentration to relative density is 1: 1, process extractum;
(6) place the spray dryer spray to do above-mentioned extractum, obtain the sugar-free granule.
The active component of medicine of the present invention can add various conventional adjuvant required when preparing different dosage form; Be prepared into any peroral dosage form commonly used like disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine, like pill, powder, tablet, capsule, oral liquid etc.
Though motherland's medical science does not have the record of primary disease name of disease, in ancient books, record its similar clinical manifestation, the new century whole nation high Chinese medicine universities and colleges' planning teaching materials " ophthalmology of Chinese medicine " are thought that primary disease is similar to and are cured nationality contained " Gu (h ǔ) eye coagulates eyeball " ancient times.Primary disease is mainly in young and middle-aged people and since the patient of this age bracket be in enter a higher school, periods such as promotion of employment and career, often stay up late all day, overworked eyes, excessive thinking.Because of liver controlling conveyance and dispersion, main muscle, harmonizing the functional activities of vital QI, the irritability bar reaches, and then QI and blood relaxes soft with smooth, muscle.If depressed emotion, depression of liver-QI loses bar and reaches, and catharsis mistake department is then qi-blood disharmony, move not smooth, qi depression to blood stasis; Transverse invasion of hyperactive liver-QI is violated spleen, or the excessive thinking impairment of the spleen, dysfunction of the spleen in transportation, and water liquid fortuneization mistake department, endogenous damp formation gathers and forms drink and give birth to expectorant, phlegm and blood stasis, venation plug knot, muscle convulsion are unfavorable, are second-class disease so occur that the order pearl is given prominence to, rotation is ineffective, look one.Therefore; Mostly the primary disease pathogenesis is qi depression to blood stasis, retention of water-damp in the body, phlegm and blood stasis, and the muscle convulsion is unfavorable, therefore; The present invention is main method of treatment with promoting QI circulation for relieving depression, activating blood and promoting diuresis, hard masses softening and resolving, the slow convulsion of Shujin; Confirm at last to be made up of Radix Curcumae, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Semen Coicis, Bulbus Fritillariae Thunbergii, Bombyx Batryticatus, Semen Litchi seven flavor Chinese medicines, and combine the pharmacology to carry out drug screening, it is evident in efficacy.
Medicament selection Radix Curcumae of the present invention, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Semen Coicis, Bulbus Fritillariae Thunbergii, Bombyx Batryticatus, Semen Litchi make up.Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat thyroid-associated ophthalmopathy.Wherein selecting Radix Curcumae for use, is because the Radix Curcumae nature and flavor are hot, bitter, cold, has the effect that promoting QI circulation for relieving depression, promoting blood circulation and stopping pain, removing heat from blood clear away heart-fire, and is called as " the blood medicine in the gas "; Select Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra for use, be because of Radix Salviae Miltiorrhizae nature and flavor hardship, be slightly cold, have the merit of removing heat from blood and promoting blood circulation blood stasis dispelling, nourishing blood to tranquillize the mind; The Radix Paeoniae Rubra nature and flavor are bitter, be slightly cold, and have the merit of clearing away heat and cooling blood, stasis-dispelling and pain-killing, and the stasis of blood in order stagnates to disappear; The Semen Coicis nature and flavor are sweet, light, are slightly cold, can promoting diuresis with drugs of tasteless flavour, again can the slow convulsion of Shujin, and reach the merit of promoting QI circulation for relieving depression, blood circulation promoting and blood stasis dispelling, promoting diuresis to eliminate damp pathogen, the slow convulsion of Shujin with Radix Curcumae, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra compatibility; Selecting Bulbus Fritillariae Thunbergii, Bombyx Batryticatus, Semen Litchi for use, is because the Bulbus Fritillariae Thunbergii nature and flavor are bitter, cold, has the merit of dissipating phlegm and resolving masses; The Bombyx Batryticatus nature and flavor are salty, hot, and are flat, have the merit of the eliminating stagnation of expellingging wind and relieving convulsion; The Semen Litchi nature and flavor are hot, and temperature has the merit of promoting QI to circulate and dispersing the agglomeration of the pathogens, dispersing cold for relieving pain.All medicines share, not only promoting QI circulation for relieving depression, blood circulation promoting and blood stasis dispelling, promoting diuresis to eliminate damp pathogen, and can dissipating phlegm and resolving masses, the slow convulsion of Shujin, reach the purpose of treating both the principal and secondary aspects of a disease, evident in efficacy to thyroid-associated ophthalmopathy.
In sum, Chinese medicine composition of the present invention can effectively reduce thyroid-associated ophthalmopathy suffer from the exophthalmos degree of eye, improve the patient tcm syndrome, alleviate eye cardinal symptom and the sign of suffering from eye, the ill symptoms incidence rate that alleviates glucocorticoid.Safe, untoward reaction is few, and is cheap, is a kind of active drug of treatment thyroid-associated ophthalmopathy.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is further specified, the specific embodiment is to the further specifying of the principle of the invention, and does not limit the present invention in any way, or similar techniques identical with the present invention all do not exceed the scope of the present invention's protection.
Embodiment 1:
The preparation of drug solns among the present invention.Get Radix Curcumae 60 gram, Radix Paeoniae Rubra 45 grams, Radix Salviae Miltiorrhizae 30 grams, Semen Coicis 120 grams, Bulbus Fritillariae Thunbergii 20 grams, Bombyx Batryticatus 15 grams, Semen Litchi 80 grams and mix, with said mixture add 8 times promptly the 2960 gram water yields decocted 1～1.5 hour, filter, it is for use to filtrate; Above-mentioned filtering residue is added 6 times of i.e. 2220 gram water yields decoctions 1～1.5 hour again, filter, it is for use to filtrate; With above-mentioned twice filtrating merge Chinese medicine composition solution.
Embodiment 2:
The preparation of Chinese medical concrete of the present invention.Get Radix Curcumae 30 gram, Radix Paeoniae Rubra 60 grams, Radix Salviae Miltiorrhizae 80 grams, Semen Coicis 60 grams, Bulbus Fritillariae Thunbergii 60 grams, Bombyx Batryticatus 10 grams, Semen Litchi 30 grams and mix, with said mixture add 8 times promptly the 2640 gram water yields decocted 1～1.5 hour, filter, it is for use to filtrate; Above-mentioned filtering residue is added 6 times of i.e. 1980 gram water yields decoctions 1～1.5 hour again, filter, it is for use to filtrate; With above-mentioned twice filtrating merge Chinese medicine composition solution; With being concentrated into relative density after the above-mentioned twice filtrating merging is 1: 1, makes extractum.
Embodiment 3:
The particulate preparation of Chinese medicine sugar-free of the present invention.Get Radix Curcumae 400 gram, Radix Paeoniae Rubra 350 grams, Radix Salviae Miltiorrhizae 300 grams, Semen Coicis 1000 grams, Bulbus Fritillariae Thunbergii 200 grams, Bombyx Batryticatus 100 grams, Semen Litchi 600 grams and mix, with said mixture add 8 times promptly the 23600 gram water yields decocted 1～1.5 hour, filter, it is for use to filtrate; Above-mentioned filtering residue is added 6 times of i.e. 17700 gram water yields decoctions 1～1.5 hour again, filter, it is for use to filtrate; With above-mentioned twice filtrating merge Chinese medicine composition solution; With being concentrated into relative density after the above-mentioned twice filtrating merging is 1: 1, makes extractum; Place the spray dryer spray to do above-mentioned extractum, make the sugar-free granule.
Embodiment 4:
The clinical efficacy of traditional Chinese medicine composition for treating thyroid-associated ophthalmopathy of the present invention and safety testing.
1. test method
1.1 this test case is included standard in:
TAO diagnostic criteria with reference to " practical Ophthalmologic Diagnostics ", " orbital disease ": eye is suffered from (1) has burning sensation, husky puckery sense, photophobia symptom such as shed tears; (2) the simple eye or eyes proptosis ocular of carrying out property; (3) eyelid swelled, retraction of upper eyelid, slow, the blink reflex minimizing of falling, bulbar conjunctiva congestion and edema; (4) extraocular muscles is got involved, limitation of activity, diplopia or stravismus are occurred; (5) CT shows 2 above extraocular muscles and is the fusiformis hypertrophy.
1.2 this test case exclusion standard:
(1) gestation, nursing women; Or the age is below 18 one full year of life.
(2) blood and urine routine, stool blood, hepatic and renal function, Electrocardioscopy are obviously unusual.
(3) mental disease maybe can not cooperation person.
(4) merge serious disease, malignant tumor such as the heart, brain, kidney, blood system.
(5) other serious oculopathy (like keratitis, glaucoma, cataract, diabetic renal papillary necrosis, uveitis, detachment of retina etc.) are arranged.
Like above any one answer choosing " being ", then this experimenter can not participate in test.
1.3 this test case is divided into groups and Therapeutic Method
1.3.1 case is divided into groups: adopt the method for random packet, MethodsThe cases enrolled is divided into test group and Primary Care matched group at random.
1.3.2 Therapeutic Method
All experimenters all keep thyroid protopathy treatment, and use the corresponding group number medicine of going into.
Primary Care matched group (hereinafter to be referred as matched group): prednisone 30mg/ time, once-a-day, 8 of mornings are oral, continuous 2 weeks; Prednisone 25mg/ time, once-a-day, 8 of mornings are oral, continuous 2 weeks; Prednisone 20mg/ time, once-a-day, 8 of mornings are oral, continuous 2 weeks; Prednisone 15mg/ time, once-a-day, 8 of mornings are oral, continuous 4 weeks; Prednisone 10mg/ time, once-a-day, 8 of mornings are oral, keep for 2 weeks and (annotate: observe though test carried out for 12 weeks.But experimental period finishes the back patient still will be continued to keep 6-8 week for 10mg/ time/day with prednisone again)
Test group: in prednisone Primary Care (method is consistent with the Primary Care matched group), sugar-free granule 1 bag that makes in the administration embodiment of the invention 3/inferior (being equivalent to crude drug 98.33 grams), three times on the one.
1.3.3 observing time
Test period was 12 weeks.
1.4 the requirement of drug combination
(1) duration of test bans use of immunosuppressant
(2) all drug combination of duration of test all should itemized record, comprise reason, time started, termination time of medicine name, dosage, use etc.
1.5 the observation index of this test
1.5.1 general health check-up project: body temperature, breathing, heart rate, blood pressure.
1.5.2 safety indexes: urine and routine blood test, stool blood, liver function (ALT), kidney merit (Cr, BUN), electrocardiogram, the treatment front and back are respectively once.
The merging disease that 1.5.3 detailed probability existed before on-test or the test back occurs.
1.5.4 any untoward reaction that the itemized record duration of test occurs, and carry out the comparison between two groups in the 28th day (all around) after the treatment.
1.5.5 laboratory detects index: free triiodothyronine (FT
3), serum free thyroxine (FT
4), thyrotropin (TSH), before and after the treatment each once, and with its average
Carry out statistical procedures comparison between two groups.
1.5.6 clinical efficacy property index and efficacy evaluation method
(1) efficacy evaluation of eyeball protrusion
Before and after treatment, respectively survey eyeball protrusion one time with the Hertel meter.
Produce effects: treatment back eyeball protrusion reduction value >=3mm;
Effectively: treatment back exophthalmos figure reduction value is 1～＜3mm;
Invalid: treatment back eyeball protrusion reduction value＜1mm.
The comparison of (2) two groups of treatment front and back TAO activeness scorings
Clinical score standard [the Bartalena L of the TAO activeness that the European thyroid eye diseas group of reference proposes; Baldeschi L; Dickinson A; Et al.Consensus statement of the European Group on Graves ' orbitopathy (EUGOGO) on management of GO.Eur J Endocrinol, 2008,158 (3): 273-285.] mark: pain behind the spontaneous eyeball; During ocular movement with pain; Eyelid is congested; Blepharoedema; The conjunctiva diffusivity is congested; Chemosis; Lacrimal caruncle swelling.More than every each 1 minute, totally 7 minutes.Before and after treatment, respectively carry out a TAO activeness scoring, and carry out statistical procedures comparison between two groups with its average
.
(3) tcm syndrome integration and efficacy evaluation
Before and after treatment, use corresponding symptom is carried out the integration evaluation, standard is following:
Distending pain in the chest and hypochondrium: no distending pain in the chest and hypochondrium, counted 0 fen; Breast is coerced slight distending pain, counts 1 fen; Distending pain in the chest and hypochondrium more obviously can be stood, and counts 2 fens; Distending pain in the chest and hypochondrium obviously is difficult to stand, and counts 3 fens;
The eyeball distending pain: no eyeball distending pain, counted 0 fen; The slight distending pain of eyeball was counted 1 fen; The eyeball distending pain more obviously can be stood, and counts 2 fens; The eyeball distending pain obviously is difficult to stand, and counts 3 fens
Irascible temperament: the asexual moment of desperation is hot-tempered, counts 0 fen; Irascible temperament was counted 1 fen once in a while; Often irascible temperament but still can automatic control was counted 2 fens; Often irascible temperament is difficult to automatic control, counts 3 fens.
Body of the tongue: light red, counted 0 fen; Purple dark, counted 1 fen.
Tongue fur: thin coating, counted 0 fen; Thick fur was counted 1 fen.
Efficacy evaluation method and standard:
Total mark * 100% before tcm syndrome curative effect rate=(total mark before the treatment-treatment back total mark)/treatment
Produce effects: treatment back tcm syndrome curative effect rate >=51%
Effectively: treatment back tcm syndrome curative effect rate 21%-50%
Invalid: treatment back tcm syndrome curative effect rate＜20%
(4) main eye manifestation integration and efficacy evaluation
Before and after treatment, use corresponding symptom is carried out the integration evaluation, standard is following:
Pain behind the spontaneous eyeball: do not have pain behind the spontaneous eyeball, counted 0 fen; Pain behind the slight spontaneous eyeball is only arranged, counted 1 fen; Pain behind the more tangible spontaneous eyeball is arranged but can stand, counted 2 fens; Pain was difficult to and can stands after tangible spontaneous eyeball was arranged, score.
During ocular movement with pain: without pain, counted 0 fen during ocular movement; Only with mild pain, counted 1 fen during ocular movement; With pain significantly but can stand, counted 2 fens during ocular movement; Be difficult to and can stand with tangible pain during ocular movement, counted 3 fens.
Eyelid is congested: the anophthalmia hyperemia of eyelid, counted 0 fen; The eyelid mild hyperaemia was counted 1 fen; Eyelid hyperemia is more obvious, counts 2 fens; Eyelid is obviously congested, counts 3 fens.
Blepharoedema: no blepharoedema, counted 0 fen; The eyelid Mild edema was counted 1 fen; Blepharoedema is more obvious, and fissura palpebrae slightly diminishes, and counts 2 fens; The obvious edema of eyelid, fissura palpebrae obviously diminishes, and eyelid is the semi-closed state, counts 3 fens.
Conjunctival congestion: no conjunctival congestion, counted 0 fen; The conjunctiva mild hyperaemia is pale red, counts 1 fen; The hyperemia of conjunctiva diffusivity more obviously takes on a red color, and counts 2 fens; The hyperemia of conjunctiva diffusivity obviously is kermesinus, petechia is arranged, and counts 3 fens.
Chemosis: no chemosis, counted 0 fen; The bulbar conjunctiva Mild edema was counted 1 fen; Chemosis is more obvious, does not protrude in outside the eyelid but have bulbar conjunctiva during catacleisis, counts 2 fens; Chemosis is obvious, has bulbar conjunctiva to protrude in outside the eyelid during catacleisis, counts 3 fens.
Retraction of upper eyelid: no upper eyelid is shunk back, and counts 0 fen; Retraction of upper eyelid amount＞1mm but≤2mm, counted 1 fen; Retraction of upper eyelid amount＞2mmm but≤3mm, counted 2 fens; Retraction of upper eyelid amount＞3mmm counted 3 fens.
Efficacy evaluation method and standard:
Total mark * 100% before main eye manifestation curative effect rate=(total mark before the treatment-treatment back total mark)/treatment
Produce effects: treatment back tcm syndrome curative effect rate >=51%
Effectively: treatment back tcm syndrome curative effect rate 21%-50%
Invalid: treatment back tcm syndrome curative effect rate＜20%
1.6 statistical method: measurement data calculating horizontal mean and standard deviation
are checked with t check or F.Relatively adopt before and after the treatment and between two groups and compare.
2 result of the tests:
2.1 clinical physical data
This test is collected observation 62 examples altogether and is met the above-mentioned thyroid-associated ophthalmopathy patient who includes standard in.The oldest person is 55 years old, and reckling is 19 years old, 35.3 years old mean age; Man's 15 examples, women 57 examples; Simple eye morbidity 2 examples, all the other are the eyes morbidity.Wherein, 36.1 years old test group average patient age, simple eye morbidity 1 example, all the other are the eyes morbidity; 35.3 years old patient's mean age of Primary Care matched group, simple eye morbidity 2 examples, all the other are the eyes morbidity.
2.2 the comparison of two groups of eyeball protrusion curative effects (seeing table 1)
Comparison
n (eye number) of table 1 liang group treatment back eyeball protrusion curative effect
Annotate: compare with matched group
*P＜0.01,
*P＜0.05
Visible from table 1, after treatment, the total effective rate of the eyeball protrusion curative effect of test group and obvious effective rate all obviously are superior to matched group, and its difference all has statistical significance (P＜0.05, P＜0.01).Explain that Chinese medicine composition of the present invention obviously is superior to matched group in the effect that improves aspect TAO patient's eyeball protrusion curative effect.
2.3 the comparison (seeing table 2) of two groups of treatment front and back TAO activeness scorings
Comparison
n (eye number) of TAO activeness scoring before and after the table 2 liang group treatment
Annotate: compare with matched group
*Compare before and after the internal therapy on the same group (P＜0.05)
△(P＜0.05)
Visible from table 2, before the treatment, its difference not statistically significant (P＞0.01) is compared in the scoring of TAO activeness between test group and matched group; Relatively interior on the same group before and after the treatment, the TAO activeness scoring after treatment of test group and matched group all has decline in various degree, its difference to have statistical significance (P＜0.05); After treatment, relatively, test group TAO activeness is marked than the obvious reduction of matched group between test group and the matched group, and its difference has statistical significance (P＜0.05).
Above presentation of results: test group and matched group patient's pathological changes activeness scoring no significant difference before treatment has comparability between two groups; The Therapeutic Method that matched group and test group are adopted all can effectively reduce the pathological changes activeness of thyroid-associated ophthalmopathy, but test group is superior to matched group in the effect that improves aspect the pathological changes activeness of thyroid-associated ophthalmopathy.
2.4 two groups of tcm syndrome integration curative effects compare (seeing table 3)
The comparison n (routine number) of table 3 liang group tcm syndrome integration curative effect
Annotate: compare with matched group
*P＜0.01
Visible from table 3, the total effective rate and the obvious effective rate of the tcm syndrome integration curative effect of test group all obviously are superior to matched group, and its difference has statistical significance (P＜0.01).Explain that Chinese medicine composition of the present invention obviously is superior to matched group in the effect that improves aspect patient's tcm syndrome.
2.5 two groups of eye cardinal symptoms and sign integration curative effect be (seeing table 4) relatively
The comparison n of table 4 liang group eye cardinal symptom and sign integration curative effect (eye number)
Annotate: compare with matched group
*P＜0.01,
*P＜0.05
Visible from table 4, the total effective rate and the obvious effective rate of the eye cardinal symptom of test group and sign integration curative effect all obviously are superior to matched group, and its difference has statistical significance (P＜0.05, P＜0.01).Explain that Chinese medicine composition of the present invention obviously is superior to matched group aspect patient's eye cardinal symptom and the sign improving.
2.6 the comparison (seeing table 5) of two groups of treatment front and back thyroid functions
Comparison
the n=31 example of thyroid function before and after the table 5 liang group treatment
Annotate: compare with matched group
*Compare before and after the internal therapy on the same group (P＜0.05)
△(P＜0.05)
Visible from table 5, before the treatment, comparison between two groups of FT3 value, FT4 value and the TSH values, the equal not statistically significant of its difference (P＞0.05).Before and after the treatment more on the same group in, the FT3 value of test group is obvious reduction before the treatment after treatment, its difference has statistical significance (P＜0.05); The THS value of test group obviously raises before the treatment after treatment, and its difference has statistical significance (P＜0.05); The FT4 value of test group is no significant difference (P＞0.05) before and after treatment.The FT3 value of matched group, FT4 value and TSH value be no significant difference (P＞0.05) before and after treatment.After the treatment, between two groups of the FT3 values, FT4 value relatively, the equal not statistically significant of its difference (P＞0.05), but TSH value test group obviously raises than matched group, its difference has statistical significance (P＜0.05).
Above presentation of results: test group and matched group patient's thyroid function no significant difference before treatment has comparability between two groups; Chinese medicine composition of the present invention can obviously reduce patient's FT3 value, rising TSH value, improves thyroid function, and obviously is superior to matched group in the effect aspect the adjusting TSH.
2.7 the comparison (seeing table 6) of two groups of ill symptoms incidence rates (%) after treatment
The comparison n=31 example of table 6 liang group adverse reaction rate
Annotate: compare with matched group
*(P＜0.05),
*(P＜0.01)
Aspect the ill symptoms incidence rate, test group is starkly lower than matched group, and its difference all has statistical significance (P＜0.05, P＜0.01).
2.8 the comparison (seeing table 7) of two groups of treatment front and back safety indexes
The comparison n=31 example of safety indexes before and after the table 7 liang group treatment
Visible from table 7, test group and matched group safety indexes before and after treatment is all normal.
To sum up, can draw following clinical research conclusion:
1, Chinese medicine composition of the present invention can effectively reduce the eyeball protrusion that thyroid-associated ophthalmopathy is suffered from eye, and the obvious effective rate of test group is 42.6%, obviously is superior to matched group (23%), and its difference has statistical significance (P＜0.01); The total effective rate of test group is 86.9%, obviously is superior to matched group (68.9%), and its difference has statistical significance (P＜0.05).
2, Chinese medicine composition of the present invention can effectively improve thyroid-associated ophthalmopathy and has a trouble in one's eyesight and become the activeness scoring, and obviously is superior to matched group (P＜0.05).
3, Chinese medicine composition of the present invention can effectively improve thyroid-associated ophthalmopathy patient's tcm syndrome.The total effective rate of tcm syndrome integration curative effect, test group are 90.3%, and matched group is 29.1%, and test group obviously is superior to matched group (P＜0.01); The obvious effective rate of tcm syndrome integration curative effect, test group are 67.7%, and matched group is 9.7%, and test group obviously is superior to matched group (P＜0.01); Explain that Chinese medicine composition of the present invention improves the patient and has remarkable advantages aspect the tcm syndrome.
4, Chinese medicine composition of the present invention can effectively improve the eye cardinal symptom and the sign integration curative effect of thyroid-associated ophthalmopathy; The total effective rate of eye cardinal symptom and sign integration curative effect; Test group is 91.8%, and matched group is 73.8%, and test group obviously is superior to matched group (P＜0.05); The obvious effective rate of eye cardinal symptom and sign integration curative effect, test group are 62.3%, and matched group is 37.7%, and test group obviously is superior to matched group (P＜0.01); Explain that Chinese medicine composition of the present invention has remarkable advantages aspect patient's eye cardinal symptom and the sign integration improving.
5, Chinese medicine composition of the present invention can obviously reduce patient's FT3 value, rising TSH value, improves patient's thyroid function, and obviously is superior to matched group (P＜0.05) in the effect aspect the adjusting TSH.
6, Chinese medicine composition ill symptoms incidence rate of the present invention is starkly lower than matched group (P＜0.05, P＜0.01).
In sum; Chinese medicine composition of the present invention not only can effectively reduce thyroid-associated ophthalmopathy and suffer from eye the most outstanding symptom---eyeball protrusion and eye cardinal symptom and sign, and can also obviously reduce TAO pathological changes activeness and mark, improve patient's tcm syndrome, alleviate patient's general malaise symptom.Safe, untoward reaction is few, and is cheap, is the active drug of treatment thyroid-associated ophthalmopathy.
Claims (4)
1. Chinese medicine composition of treating thyroid-associated ophthalmopathy; It is characterized in that compositions is processed by the Chinese medicine of following portions by weight: Radix Curcumae 30-60 part, Radix Paeoniae Rubra 30-60 part, Radix Salviae Miltiorrhizae 30-80 part, Semen Coicis 60-120 part, Bulbus Fritillariae Thunbergii 20-60 part, Bombyx Batryticatus 10-30 part, Semen Litchi 30-80 part.
2. the Chinese medicine composition of treatment thyroid-associated ophthalmopathy according to claim 1; It is characterized in that compositions is processed by the Chinese medicine of following portions by weight: 60 parts of Radix Curcumaes, 45 parts of Radix Paeoniae Rubra, 30 parts of Radix Salviae Miltiorrhizaes, 120 parts of Semen Coiciss, 20 parts of Bulbus Fritillariae Thunbergiis, 15 parts of Bombyx Batryticatus, 80 parts of Semen Litchis.
3. aforesaid right requires 1 or the method for preparing of claim 2 Chinese medicine composition, it is characterized in that may further comprise the steps:
(1) gets each component and mix homogeneously by claim 1 or the said combination weight umber of claim 2;
(2) 8 times of water yields of step (1) mixture totalling parts by weight were decocted 1～1.5 hour, filter, it is for use to filtrate;
(3) step (2) filtering residue is added 6 times of water yields of step (1) mixture total weight amount umber again and decocted 1～1.5 hour, filter, it is for use to filtrate;
(4) with above-mentioned twice filtrating merge Chinese medicine composition solution;
(5) merge step (4) to such an extent that Chinese medicine composition solution concentration to relative density is 1: 1, process extractum;
(6) place the spray dryer spray to do above-mentioned extractum, obtain the sugar-free granule.
4. the application of Chinese medicine composition according to claim 1 and 2 in the medicine of preparation treatment thyroid-associated ophthalmopathy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100548642A CN102631623B (en) | 2012-03-05 | 2012-03-05 | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100548642A CN102631623B (en) | 2012-03-05 | 2012-03-05 | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631623A true CN102631623A (en) | 2012-08-15 |
| CN102631623B CN102631623B (en) | 2013-07-03 |
Family
ID=46616306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100548642A Expired - Fee Related CN102631623B (en) | 2012-03-05 | 2012-03-05 | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631623B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432531A (en) * | 2013-09-06 | 2013-12-11 | 河南中医学院 | Traditional Chinese medicine for treating thyroid-associated ophthalmopathy used in stable phase |
| CN103446543A (en) * | 2013-09-06 | 2013-12-18 | 河南中医学院 | Traditional Chinese medicine for treating thyroid associated ophthalmopathy in acute stage |
| CN107050377A (en) * | 2017-02-14 | 2017-08-18 | 四川双鑫生物科技有限公司 | A kind of new medicine composition and preparation method for treating thyroid-associated ophthalmopathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530489A (en) * | 2008-03-13 | 2009-09-16 | 上海中医药大学附属龙华医院 | Chinese medicine composition used for treating non-active stage infiltrative exophthalmos of thyroid-associated ophthalmopathy and preparation method thereof |
-
2012
- 2012-03-05 CN CN2012100548642A patent/CN102631623B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101530489A (en) * | 2008-03-13 | 2009-09-16 | 上海中医药大学附属龙华医院 | Chinese medicine composition used for treating non-active stage infiltrative exophthalmos of thyroid-associated ophthalmopathy and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 薛科辉: "中医药治疗甲亢突眼的进展", 《湖南中医杂志》 * |
| 陈虹林: "中医药治疗甲状腺相关眼病现状", 《现代中西医结合杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103432531A (en) * | 2013-09-06 | 2013-12-11 | 河南中医学院 | Traditional Chinese medicine for treating thyroid-associated ophthalmopathy used in stable phase |
| CN103446543A (en) * | 2013-09-06 | 2013-12-18 | 河南中医学院 | Traditional Chinese medicine for treating thyroid associated ophthalmopathy in acute stage |
| CN103446543B (en) * | 2013-09-06 | 2015-04-01 | 河南中医学院 | Traditional Chinese medicine for treating thyroid associated ophthalmopathy in acute stage |
| CN103432531B (en) * | 2013-09-06 | 2015-05-20 | 河南中医学院 | Traditional Chinese medicine for treating thyroid-associated ophthalmopathy used in stable phase |
| CN107050377A (en) * | 2017-02-14 | 2017-08-18 | 四川双鑫生物科技有限公司 | A kind of new medicine composition and preparation method for treating thyroid-associated ophthalmopathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631623B (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444611B (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN102698079B (en) | Medicine composition for treating xerophthalmia and preparation method and application thereof | |
| AU2018364749C1 (en) | Use of riluzole prodrugs to treat ataxias | |
| CN102631623B (en) | Traditional Chinese medicine composite for treating thyroid associated ophthalmopathy and preparation method thereof | |
| CN105031212A (en) | Drug for treating parkinson disease | |
| CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
| CN102846871B (en) | Chinese herbal preparation for treating liver-fire ascending type supraorbital neuralgia and preparation method thereof | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN104906220A (en) | Traditional Chinese medicine for treating herpes zoster and herpes simplex viral keratitis | |
| CN104524000B (en) | It is a kind of to improve improving eyesight rapid-released droppills of visual fatigue and preparation method thereof rapidly | |
| CN113648351A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing/treating macular degeneration diseases | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| CN103251725B (en) | A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared | |
| CN102210841A (en) | Chinese medicinal preparation for treating central serous retinopathy | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN100581581C (en) | Technique for preparing Chinese traditional medicine and pills for clearing away heart-fire, dispersing phlegm, tranquilizing the mind, and reducing blood pressure | |
| CN104623309A (en) | Traditional Chinese medicine preparation for treating xerophthalmia | |
| CN112294963B (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN103961609A (en) | Difenidol hydrochloride and preparation method thereof | |
| CN103990044B (en) | A kind of Chinese medicine composition for treating epilepsy, its preparation method, preparation and application | |
| CN106581445A (en) | Traditional Chinese medicine prescription for treating diabetic retinopathy | |
| CN105833064A (en) | Eyesight-improving decoction for treating diabetic retinopathy | |
| Babadjanova et al. | Etiopathogenetic and clinical characteristics of diffuse toxic goiter | |
| CN102068595A (en) | New application of Chinese medicinal composition to treatment of vascular dementia | |
| CN115737725A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130703 Termination date: 20170305 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |